Press Releases

Press Releases

Date Title
December 4, 2018
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors
Appointment Adds Significant Scientific Breadth to Board SAN FRANCISCO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the
December 3, 2018
UNITY Biotechnology Announces Additional Cohort to Evaluate Higher Dose in Ongoing UBX0101 Phase 1 Study in Osteoarthritis of the Knee
Initial study results expected to be available in second quarter of 2019 SAN FRANCISCO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today
November 13, 2018
UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence
- Event will be webcast live - SAN FRANCISCO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will host an Investor &
November 7, 2018
UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results
SAN FRANCISCO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported third quarter 2018 financial results.
October 31, 2018
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results
SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the third quarter ended September 30, 2018 , on
September 24, 2018
UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference
SAN FRANCISCO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Bob Goeltz , chief financial officer, will present a
September 5, 2018
UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference

SAN FRANCISCO , Sept. 05, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard , chairman and chief executive officer,

August 9, 2018
UNITY Biotechnology, Inc. Reports Second Quarter 2018 Financial Results

SAN FRANCISCO , Aug. 09, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported second quarter 2018 financial results.

July 31, 2018
UNITY Biotechnology, Inc. to Announce Second Quarter 2018 Financial Results

SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended June 30, 2018 ,

June 25, 2018
UNITY Biotechnology, Inc. Announces First Patient Treated in UBX0101 Phase 1 Trial for Osteoarthritis of the Knee

First UNITY Clinical Trial Designed to Eliminate Senescent Cells Associated with Age-Related Diseases SAN FRANCISCO , June 25, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or

Displaying 1 - 10 of 20